The Importance of Engaging Stakeholders When Implementing Bispecific Antibodies

Matthew Pianko, MD, outlines the logistical considerations involved when implementing bispecific antibodies for the treatment of multiple myeloma, including the roles of the project champion and other stakeholders as part of a multidisciplinary team.

Related Keywords

Michigan ,United States ,Matthew Pianko ,Anthony Perissinotti ,Ryan Haumschild ,University Of Michigan Health ,Practice Pearls ,Michigan Health ,Pharmacy Times ,Physician Champion ,Project Champion ,Bispecific Antibodies ,Implementation ,Step Up Dosing ,Multidisciplinary Care ,Crs ,Cytokine Release Syndrome ,Hematologist ,Oncologist ,Chemotherapy ,Outpatient ,Inpatient ,Supportive Care ,